{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:26:20Z","timestamp":1776918380453,"version":"3.51.2"},"reference-count":30,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.clinthera.2024.09.001","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T17:17:26Z","timestamp":1728407846000},"page":"900-904","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Topical Application of 0.05% Cyclosporine for the Treatment of Neurotrophic Keratopathy Secondary to Herpes Simplex Keratitis"],"prefix":"10.1016","volume":"46","author":[{"given":"Ruochen","family":"Liao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqi","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruifeng","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2602-8509","authenticated-orcid":false,"given":"Xiaobo","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.09.001_bib0001","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.eye.6700616","article-title":"Neurotrophic keratitis","volume":"17","author":"Bonini","year":"2003","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.clinthera.2024.09.001_bib0002","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1177\/1120672120921379","article-title":"Fast and sustained healing of resistant corneal ulcers using corneal scrubbing and matrix regenerating therapy","volume":"31","author":"Lazreg","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.clinthera.2024.09.001_bib0003","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.optm.2006.05.001","article-title":"Therapeutic options for the management of early neurotrophic keratopathy: a case report and review","volume":"77","author":"Reynolds","year":"2006","journal-title":"Optometry"},{"key":"10.1016\/j.clinthera.2024.09.001_bib0004","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1177\/11206721221097584","article-title":"Clinical and instrumental assessment of the corneal healing in moderate and severe neurotrophic keratopathy treated with rh-NGF (Cenegermin)","volume":"32","author":"Roszkowska","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.clinthera.2024.09.001_bib0005","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/ICU.0000000000000766","article-title":"The management of neurotrophic keratitis","volume":"32","author":"Jabbour","year":"2021","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.clinthera.2024.09.001_bib0006","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jtos.2019.11.008","article-title":"Neurotrophic keratitis: frequency, etiologies, clinical management and outcomes","volume":"18","author":"Saad","year":"2020","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clinthera.2024.09.001_bib0007","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1167\/iovs.61.3.21","article-title":"Corneal sensitivity and tear function in recurrent corneal erosion syndrome","volume":"61","author":"Kang","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.clinthera.2024.09.001_bib0008","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000354380","article-title":"Neurotrophic keratitis","volume":"231","author":"Semeraro","year":"2014","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.clinthera.2024.09.001_bib0009","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1080\/07853890.2022.2045035","article-title":"Neurotrophic keratopathy: current challenges and future prospects","volume":"54","author":"NaPier","year":"2022","journal-title":"Ann Med"},{"key":"10.1016\/j.clinthera.2024.09.001_bib0010","first-page":"205","article-title":"Corneal melts associated with topically applied nonsteroidal anti-inflammatory drugs","volume":"99","author":"Flach","year":"2001","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.clinthera.2024.09.001_bib0011","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1084\/jem.193.5.607","article-title":"Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2","volume":"193","author":"Hern\u00e1ndez","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.clinthera.2024.09.001_bib0012","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1159\/000268041","article-title":"Topical cyclosporin as an adjunct to topical acyclovir treatment in herpetic stromal keratitis","volume":"29","author":"G\u00fcnd\u00fcz","year":"1997","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.clinthera.2024.09.001_bib0013","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.ajo.2005.11.042","article-title":"Treatment of herpes simplex virus stromal keratitis unresponsive to topical prednisolone 1% with topical cyclosporine 0.05%","volume":"141","author":"Rao","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2024.09.001_bib0014","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s004170050257","article-title":"Treatment of HSV-1 stromal keratitis with topical cyclosporin A: a pilot study","volume":"237","author":"Heiligenhaus","year":"1999","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.clinthera.2024.09.001_bib0015","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.survophthal.2008.12.004","article-title":"Management of herpes simplex virus stromal keratitis: an evidence-based review","volume":"54","author":"Knickelbein","year":"2009","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.clinthera.2024.09.001_bib0016","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/00055735-199908000-00009","article-title":"Management of neurotrophic keratopathy","volume":"10","author":"Lambiase","year":"1999","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.clinthera.2024.09.001_bib0017","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40265-020-01289-w","article-title":"Cenegermin: a review in neurotrophic keratitis","volume":"80","author":"Deeks","year":"2020","journal-title":"Drugs"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2024.09.001_bib0018","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/ICO.0b013e3182281028","article-title":"Cyclosporine A induces nerve growth factor expression via activation of MAPK p38 and NFAT5","volume":"30","author":"Lee","year":"2011","journal-title":"Cornea"},{"key":"10.1016\/j.clinthera.2024.09.001_bib0019","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0002-9394(14)71169-9","article-title":"Reversal of abnormal corneal epithelial cell morphologic characteristics and reduced corneal sensitivity in diabetic patients by aldose reductase inhibitor, CT-112","volume":"119","author":"Hosotani","year":"1995","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2024.09.001_bib0020","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/00003226-199707000-00009","article-title":"Topical anesthetic abuse ring keratitis: report of four cases","volume":"16","author":"Varga","year":"1997","journal-title":"Cornea"},{"key":"10.1016\/j.clinthera.2024.09.001_bib0021","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1055\/s-2001-18663","article-title":"Autologous serum for otherwise therapy resistant corneal epithelial defects \u2013 prospective report on the first 70 eyes","volume":"218","author":"Ferreira de Souza","year":"2001","journal-title":"Klin Monbl Augenheilkd"},{"key":"10.1016\/j.clinthera.2024.09.001_bib0022","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II management and therapy report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clinthera.2024.09.001_bib0023","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1517\/14656566.5.10.2099","article-title":"Topical 0.05% cyclosporin in the treatment of dry eye","volume":"5","author":"Perry","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2024.09.001_bib0024","first-page":"571","article-title":"Diagnosis and management of neurotrophic keratitis","volume":"8","author":"Sacchetti","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.clinthera.2024.09.001_bib0025","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1177\/11206721221141481","article-title":"Management of inflammation in dry eye disease: recommendations from a European panel of experts","volume":"33","author":"Messmer","year":"2023","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.clinthera.2024.09.001_bib0026","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2165\/00003495-199345060-00007","article-title":"A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders","volume":"45","author":"Faulds","year":"1993","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2024.09.001_bib0027","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.preteyeres.2018.04.003","article-title":"Neurotrophic keratopathy","volume":"66","author":"Dua","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.clinthera.2024.09.001_bib0028","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.sjopt.2014.06.011","article-title":"Management strategies for persistent epithelial defects of the cornea","volume":"28","author":"Katzman","year":"2014","journal-title":"Saudi J Ophthalmol"},{"key":"10.1016\/j.clinthera.2024.09.001_bib0029","first-page":"980","article-title":"Curative effect assessment of bandage contact lens in neurogenic keratitis","volume":"7","author":"Sun","year":"2014","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.clinthera.2024.09.001_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.796854","article-title":"New pharmacological approaches for the treatment of neurotrophic keratitis","volume":"13","author":"Koay","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T01:03:11Z","timestamp":1732410191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824002625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0149291824002625"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.09.001","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical Application of 0.05% Cyclosporine for the Treatment of Neurotrophic Keratopathy Secondary to Herpes Simplex Keratitis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}